Keyur PatelAlexander J. ThompsonWan Long ChuangChuan Mo LeeChen Yuan PengGanesananthan ShanmuganathanSatawat ThongsawatTawesak TanwandeeVarocha MahachaiChutima PramoolsinsapMong ChoKwang Hyup HanSamir R. ShahGraham R. FosterPaul J. ClarkErik PulkstenisG. Mani SubramanianJohn G. MchutchisonDuke Clinical Research InstituteHGSKaohsiung Medical University Chung-Ho Memorial HospitalChang Gung University College of MedicineChina Medical University Hospital TaichungKuala Lumpur HospitalChiang Mai UniversityFaculty of Medicine, Siriraj Hospital, Mahidol UniversityChulalongkorn UniversityMahidol UniversityPusan National UniversityYonsei UniversityJaslok Hospital and Research CentreQueen Mary, University of London2018-05-032018-05-032011-01-01Journal of Gastroenterology and Hepatology (Australia). Vol.26, No.7 (2011), 1182-118814401746081593192-s2.0-79958783189https://repository.li.mahidol.ac.th/handle/123456789/12781Background and Aim: The role of insulin resistance (IR) and hepatic steatosis in fibrogenesis in chronic hepatitis C infection (CHC) has yielded conflicting data and few studies have been performed in Asian-region populations. We retrospectively investigated the relationship between host metabolic variables, including IR and hepatic steatosis, to hepatic fibrosis in Asian-region CHC genotype 2/3 patients. Methods: A total of 303 treatment-naïve Asian-region patients with CHC genotype 2/3 were enrolled in a multicenter phase 3 study of albinterferon alfa-2b plus ribavirin for 24weeks. IR was defined as Homeostasis Model for Assessment of IR (HOMA-IR) > 2. Baseline liver biopsy was evaluated by a single expert histopathologist. Post hoc subgroup logistic regression modeling selected for independent variables associated with significant fibrosis (METAVIR stage F2-F4). Results: Insulin resistance was available in 263 non-diabetic Asian-region patients (hepatitis C virus-2 [HCV-2]=171, HCV-3=92), and 433 non-Asian region patients (407 "Caucasian"); METAVIR fibrosis prevalence F0-F1 (minimal fibrosis)=201 (77%) and F2-F4 (significant fibrosis)=59 (23%), and steatosis prevalence of grade 0=169 (65%), grade 1=64 (25%), grade 2/3=27 (10%). Median HOMA-IR was 1.8 (interquartile range: 1.2-2.7); 100 (38%) patients had HOMA-IR > 2. Factors independently associated with significant fibrosis included HOMA-IR (odds ratio [OR]=8.42), necro-inflammatory grade (OR=3.17), age (OR=1.07) and serum total cholesterol levels (OR=0.008). This was similar to non-Asian region patients, but steatosis was not associated with significant fibrosis in either cohort. Conclusions: In this subgroup study of Asian-region HCV genotype 2 or 3 patients, insulin resistance, along with age, cholesterol levels and necro-inflammation, but not steatosis may be associated with significant hepatic fibrosis. © 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.Mahidol UniversityMedicineArticleSCOPUS10.1111/j.1440-1746.2011.06722.x